Is statin-induced diabetes clinically relevant? A comprehensive review of the literature

被引:26
作者
Bell, D. S. H. [1 ]
DiNicolantonio, J. J. [2 ]
O'Keefe, J. H. [3 ]
机构
[1] Univ Alabama Birmingham, Southside Endocrinol, Birmingham, AL 35213 USA
[2] St Lukes Hosp, Mid Amer Heart Inst, Kansas City, MO 64111 USA
[3] Univ Missouri, St Lukes Hosp, Mid Amer Heart Inst, Kansas City, MO 64110 USA
关键词
diabetes mellitus; drug mechanism; drug utilization; CARDIOVASCULAR EVENTS; INSULIN SENSITIVITY; PRIMARY PREVENTION; ADIPONECTIN LEVELS; PLASMA-GLUCOSE; PRAVASTATIN; ATORVASTATIN; ROSUVASTATIN; CORONARY; PITAVASTATIN;
D O I
10.1111/dom.12254
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In those predisposed to the development of diabetes (the insulin resistant, obese and older patients) statins may increase the risk of developing diabetes. Despite the fact that the conversion to diabetes is generated from post hoc analyses, it seems to be a class effect with a dose-response relationship. However, statins have not been clearly shown to increase diabetic microvascular complications (retinopathy, nephropathy and neuropathy). Thus, the clinical significance of increased glucose levels in patients treated on statins is uncertain. While the exact mechanism for how statins increase the risk of diabetes is unknown, a possible explanation is through a reduction in adiponectin levels. Despite the fact that higher statin doses are more likely to lead to new-onset diabetes, for every case of diabetes caused, there are approximately three cardiovascular events reduced with high dose versus moderate dose statin therapy. Overall, the small risk of developing type 2 diabetes with statin therapy is far outweighed by the potential of statins to decrease cardiac events.
引用
收藏
页码:689 / 694
页数:6
相关论文
共 53 条
[1]   Rediscovering bile acid sequestrants [J].
Bell, D. S. H. ;
O'Keefe, James H. .
DIABETES OBESITY & METABOLISM, 2009, 11 (12) :1114-1121
[2]  
Bell David S H, 2008, Endocr Pract, V14, P112
[3]   Atorvastatin administration after percutaneous coronary intervention in patients with coronary artery disease and normal lipid profiles: Impact on plasma adiponectin level [J].
Chan, Kuei-Chuan ;
Chou, Hsi-Hsien ;
Huang, Chien-Ning ;
Chou, Ming-Chih .
CLINICAL CARDIOLOGY, 2008, 31 (06) :253-258
[4]   Statins of high versus low cholesterol-lowering efficacy and the development of severe renal failure [J].
Chung, Yu-Heng ;
Lee, Yen-Chieh ;
Chang, Chia-Hsuin ;
Lin, Min-Shung ;
Lin, Jou-Wei ;
Lai, Mei-Shu .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 (06) :583-592
[5]  
Collins R, 2003, LANCET, V361, P2005
[6]   Beneficial cardiovascular pleiotropic effects of statins [J].
Davignon, J .
CIRCULATION, 2004, 109 (23) :39-43
[7]   Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels - Results of AFCAPS/TexCAPS [J].
Downs, JR ;
Clearfield, M ;
Weis, S ;
Whitney, E ;
Shapiro, DR ;
Beere, PA ;
Langendorfer, A ;
Stein, EA ;
Kruyer, W ;
Gotto, AM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (20) :1615-1622
[8]   Statins and coenzyme Q10 [J].
Ellis, CJ ;
Scott, R .
LANCET, 2003, 361 (9363) :1134-1135
[9]   A prospective study of pravastatin in the elderly at risk (PROSPER): Screening experience and baseline characteristics [J].
Ford, I ;
Blauw, GJ ;
Murphy, MB ;
Shepherd, J ;
Cobbe, SM ;
Bollen, ELEM ;
Buckley, BM ;
Jukema, JW ;
Hyland, M ;
Gaw, A ;
Lagaay, AM ;
Perry, IJ ;
Macfarlane, PW ;
Norrie, J ;
Meinders, AE ;
Sweeney, BJ ;
Packard, CJ ;
Westendorp, RGJ ;
Twomey, C ;
Stott, DJ .
CURRENT CONTROLLED TRIALS IN CARDIOVASCULAR MEDICINE, 2002, 3 (1)
[10]   Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk -: the PIOSTAT study [J].
Forst, Thomas ;
Pfuetzner, Andreas ;
Luebben, Georg ;
Weber, Matthias ;
Marx, Nikolaus ;
Karagiannis, Efstrathios ;
Koehler, Carsta ;
Baurecht, Werner ;
Hollberg, Cloth ;
Hanefeld, Markolf .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2007, 56 (04) :491-496